Virtu KCG Holdings’s Esperion Therapeutics ESPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$419K Sell
9,047
-30,149
-77% -$1.11M 0.01% 1313
2017
Q1
$1.38M Buy
+39,196
New +$898K 0.04% 480
2016
Q3
– Sell
-41,780
Closed -$413K – 3167
2016
Q2
$413K Buy
+41,780
New +$692K 0.01% 1558
2016
Q1
– Sell
-10,296
Closed -$229K – 3040
2015
Q4
$229K Sell
10,296
-14,904
-59% -$376K ﹤0.01% 2523
2015
Q3
$594K Buy
+25,200
New +$1.58M 0.01% 1361

Other funds holding ESPR

Virtu KCG Holdings's ESPR Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Esperion Therapeutics (ESPR) stake by 77% in Q2 2017, selling an estimated $1.11M and leaving 9,047 shares worth $419K. The position accounts for 0.01% of the portfolio, ranked #1313.

Virtu KCG Holdings first reported a position in ESPR in Q3 2015 and has held it in 5 quarters since. The position peaked at $1.38M in Q1 2017. 131 funds tracked by Wall St. Rank hold ESPR as of Q2 2017.

  • Virtu KCG Holdings held 9,047 shares of Esperion Therapeutics worth $419K as of Q2 2017.
  • Virtu KCG Holdings sold 30,149 Esperion Therapeutics shares in Q2 2017, an estimated $1.11M.
  • Esperion Therapeutics made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1313 holding.
  • Virtu KCG Holdings first reported a position in Esperion Therapeutics in Q3 2015 and has held it in 5 quarters since.
  • Virtu KCG Holdings's Esperion Therapeutics position peaked at $1.38M in Q1 2017.
  • 131 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.